IMS Health is a global company that provides information, services and technology for the healthcare industry.

IMS Health was founded in 1954 by Bill Frohlich and David Dubow. In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners. Ari Bousbib is IMS Healths Chairman and Chief Executive Officer. Bousbib, a long-time senior executive at United Technologies Corporation,[2] joined IMS in September 2010.IMS Health recently moved its headquarters from Norwalk, CT to Danbury, CT.[4]

Products and Service

IMS Health provides analytics, on-shore and off-shore commercial services, and business intelligence platforms to its healthcare clients in more than 100 countries. IMSs products and services are used by companies to develop commercialization plans and portfolio strategies to select relevant patient and physician populationsfor specific therapies, and to measure the effectiveness of pharmaceutical marketing and sales resources. IMS also uses their own data to produce syndicated reports such as market forecasts. These predict how a market in a specific country or specific therapy area will change over time. This works through the production of baseline projections of sales and the application of different future events to this baseline to produce a forecast.

History and acquisitions

The original name of the company was Intercontinental Marketing Services, hence the IMS moniker. IMS Health's corporate headquarters is located in Danbury, Connecticut. The company's chairman and chief executive officer is Ari Bousbib.
y y

y y y y

In 2002, IMS acquired Cambridge Pharma Consultancy, a privately held international firm that provides strategic advice to senior pharmaceutical management. In 2003, the company acquired Marketing Initiatives, a specialist in healthcare facility profile data, and Data Niche Associates, a provider of rebate validation services for Medicaid and managed care. In 2004, United Research China Shanghai was acquired, providing coverage of Chinas consumer health market. In 2005, IMS acquired PharMetrics, a U.S. provider of patient-centric integrated claims data. In 2006, the company acquired the Life Sciences practice of Strategic Decisions Group, a portfolio strategy consultant to the life sciences industry. In 2007, IMS acquired IHS and MedInitiatives, providers of healthcare data management analytics and technology services. That same year, ValueMedics Research was acquired, extending IMSs health economics and outcomes research capabilities. In 2007, IMS was ranked in The Business Week 50. This list represents "best in class" companies from the ten economic sectors that make up the S&P 500.

y y y

y y y

In 2008, IMS is named to the Worlds Most Admired Companies list by Fortune (magazine). The company received the recognition again in 2010. In 2008, IMS acquired RMBC, a provider of national pharmaceutical market intelligence and analytics in Russia. In 2009, IMS is named to the Dow Jones Sustainability North America Index in recognition of the companys economic, environmental and social performance among the largest 600 North American companies. In February 2010, IMS Health was taken private by TPG Capital, CPP Investment Board, and Leonard Green & Partners. In 2010, IMS acquired Brogan, Inc., a privately held market research and consulting firm serving the Canada healthcare market. In 2011, IMS expanded its specialty and patient-level data assets in the U.S. with the acquisition of SDI Health. Also that year, the company acquired Ardentia Ltd in the U.K., and Med-Vantage in the U.S. to build on its payer services in those markets. For 2012, IMS Consulting Group was rated as #2 in Vault's 'Pharmaceutical & Healthcare Consulting Companies' 2012 rankings.

Industry Rankings
In 2011, IMS ranked fourth on IDC Health Insights list of top 5 preferred life science technology vendors for IT services (Perspective: IDC Health Insights' Top 5 Preferred Life Science Technology Vendors for 2011, Eric Newmark, Program Director Business Systems Strategies, Perspective #HI229400 The ranking is based on the global market intelligence firms survey of 135 industry leaders on their planned IT spend:

IDC Health Insights' Top 5 Preferred Life Science Technology Vendors for 2011
Table 1: Top 5 Life Science Vendors, 2011 Hardware % of Ranking Vendor Respondents 1 Dell 47.8 2 HP 32.2 3 Apple 27.8 4 IBM 22.6 5 Cisco 22.6 Software % of Vendor Respondents Oracle 29.6 SAP 15.7 SAS 10.4 Microsoft 9.6 Apple 9.6 IT Services % of Vendor Respondents Accenture 7.8 IBM 7 HP 4.3 IMS 2.6 Cognizant 1.7

Top 10 of the Market Research Sector 2009

Rank 1 2 3 4 5 6 7 8 9

Sales in 2009 Growth in % (million USD) Nielsen Company 5,000.0 2.6 Kantar Group 2,000 2.5 IMS Health Inc. 1,958.6 8.9 GfK AG 1,397.3 5.4 Ipsos 1,077.0 6.5 Synovate 739.6 9.5 IRI 665.0 6.6 Westat 425.8 0.8 Arbitron 400.0 5.9 Company

Industry Studies
Drug shortages in the U.S. are limited primarily to generic injectables and a few key disease areas, according to a 2011 IMS Institute for Healthcare Informatics study Affected products represent a small part of the overall medicines market but include a number of critical drugs used to treat cancer, infection, cardiovascular disease, central nervous system conditions and pain. Although almost 100 companies were supplying the 168 products in short supply, half of those drugs were made by only one or two suppliers. The analysis made use of IMS Healths database of U.S. prescription sales, and shortages lists compiled by the U.S. FDA and American Society of Health-System Pharmacists.

References and external links

1. 2. 3. 4. 5. ^ "IMS Health sold to TPG, CPPIB, LG&P" ^ "CEO's of Tomorrow" ^ http://www.businessweek.com/magazine/content/10_36/b4193016891032.htm ^ "IMS Health moves headquarters to Danbury" ^ Drive to Develop New Commercial Models.pdf "The Drive to Develop New Commericial Models" 6. ^ in the News/Documents/Kleinrock, 2011 CA Biomed Industry Report_FINAL.pdf "CA Biomed Industry Report"